Amundi Asset Management US’s Charles River Laboratories CRL Stock Holding History

Amundi Asset Management US’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$33.3M	Buy	114,950 +10,244	+10%	+$2.85M	0.03%	528
2020 Q4	$26.2M	Buy	104,706 +18,158	+21%	+$4.32M	0.02%	556
2020 Q3	$19.6M	Buy	86,548 +79,852	+1,193%	+$16.6M	0.02%	555
2020 Q2	$1.17M	Buy	6,696 +1,831	+38%	+$292K	﹤0.01%	1164
2020 Q1	$614K	Buy	4,865 +914	+23%	+$137K	﹤0.01%	1169
2019 Q4	$604K	Hold	3,951	–	–	﹤0.01%	1317
2019 Q3	$523K	Sell	3,951 -37,640	-91%	-$5.05M	﹤0.01%	1317
2019 Q2	$5.9M	Buy	41,591 +37,252	+859%	+$5.05M	﹤0.01%	903
2019 Q1	$630K	Sell	4,339 -38,321	-90%	-$5.03M	﹤0.01%	1288
2018 Q4	$4.83K	Buy	42,660 +17,222	+68%	+$2.16M	﹤0.01%	839
2018 Q3	$3.42M	Buy	+25,438	New	+$3.14M	﹤0.01%	1009
2018 Q2	–	Sell	-17,159	Closed	-$1.83M	–	1577
2018 Q1	$1.83M	Sell	17,159 -172,911	-91%	-$18.6M	﹤0.01%	1078
2017 Q4	$20.8M	Buy	190,070 +58,409	+44%	+$6.36M	0.03%	450
2017 Q3	$14.2M	Buy	131,661 +32,551	+33%	+$3.34M	0.05%	252
2017 Q2	$10M	Sell	99,110 -64,615	-39%	-$5.95M	0.03%	314
2017 Q1	$14.7M	Sell	163,725 -698	-0.4%	-$59.3K	0.05%	252
2016 Q4	$12.5M	Sell	164,423 -133,286	-45%	-$10.1M	0.04%	271
2016 Q3	$24.8M	Buy	297,709 +25,983	+10%	+$2.18M	0.09%	192
2016 Q2	$22.4M	Sell	271,726 -21,772	-7%	-$1.79M	0.08%	196
2016 Q1	$22.3M	Buy	293,498 +1,153	+0.4%	+$85.3K	0.08%	193
2015 Q4	$23.5M	Sell	292,345 -462	-0.2%	-$33.3K	0.09%	194
2015 Q3	$18.6M	Buy	292,807 +47,945	+20%	+$3.44M	0.08%	238
2015 Q2	$17.2M	Buy	244,862 +42,767	+21%	+$3.16M	0.06%	269
2015 Q1	$16M	Sell	202,095 -41,279	-17%	-$3.05M	0.06%	287
2014 Q4	$15.5M	Buy	243,374 +21,758	+10%	+$1.36M	0.06%	294
2014 Q3	$13.2M	Buy	221,616 +98,439	+80%	+$5.63M	0.05%	303
2014 Q2	$6.59M	Sell	123,177 -40,690	-25%	-$2.23M	0.03%	416
2014 Q1	$9.89M	Buy	163,867 +32,658	+25%	+$1.9M	0.04%	341
2013 Q4	$6.96M	Buy	131,209 +29,997	+30%	+$1.51M	0.03%	397
2013 Q3	$4.68M	Buy	101,212 +55,312	+121%	+$2.54M	0.02%	467
2013 Q2	$1.88M	Buy	+45,900	New	+$1.97M	0.01%	540

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Amundi Asset Management US's CRL Position: Q1 2021 in Review

Amundi Asset Management US increased its Charles River Laboratories (CRL) stake by 9.8% in Q1 2021, buying an estimated $2.85M and bringing the position to 114,950 shares worth $33.3M. The position accounts for 0.03% of the portfolio, ranked #528.

Amundi Asset Management US first reported a position in CRL in Q2 2013 and has held it in 31 quarters since. 562 funds tracked by Wall St. Rank hold CRL as of Q1 2021.

Amundi Asset Management US held 114,950 shares of Charles River Laboratories worth $33.3M as of Q1 2021.
Amundi Asset Management US bought 10,244 Charles River Laboratories shares in Q1 2021, an estimated $2.85M.
Charles River Laboratories made up 0.03% of Amundi Asset Management US's portfolio in Q1 2021, its #528 holding.
Amundi Asset Management US first reported a position in Charles River Laboratories in Q2 2013 and has held it in 31 quarters since.
562 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.